Home > News > Foreword – Oncology & Hematology Review (US), 2013;9(1):5
Breast Cancer
Read Time: 2 mins

Foreword – Oncology & Hematology Review (US), 2013;9(1):5

Published Online: June 15th 2013
Authors: Charles D Lopez
Quick Links:
Article
Article Information
Article:

This issue of Oncology & Hematology Review covers a wide variety of topics on neoplastic diseases. an underlying theme to many of these timely articles is a snapshot of ongoing trials, as well as a glimpse into the future of potential new therapies within these important subspecialties.

Prostate Cancer

This issue of Oncology & Hematology Review covers a wide variety of topics on neoplastic diseases. an underlying theme to many of these timely articles is a snapshot of ongoing trials, as well as a glimpse into the future of potential new therapies within these important subspecialties.

Prostate Cancer
Bologna et al. present data assessing the value of serum leptin as a risk factor for prostate cancer, which could be important for future biomarker development. Westesson and Stephenson review the salvage therapy treatment options after the clinically important, and not uncommon, scenario of prostate cancer recurrence after initial definitive treatment. Koletsky provides an overview on the treatment of castrate-resistant metastatic prostate cancer with an emphasis on the recent advances using approved novel agents as well as those currently under investigation.

Breast Cancer
Gradisher summarizes the preclinical and clinical data on nab-paclitaxel and provides a perspective on its growing role in the management of metastatic breast cancer.

Lung Cancer
Mellema et al. speculate on the use of sorafenib in metastatic non-small cell lung cancer. They review the completed clinical trials as well as the ongoing combination trials with other targeted agents.

Rectal Cancer
Overton and colleagues summarize the evolution of the complex multimodality treatment for rectal cancer. importantly, they also discuss the thought-provoking concept of organ-sparing approaches given recent data, ongoing trials, and future trials attempting to increase efficacy and minimize toxicities.

Esophageal Cancer
liu and Gibson provide an update on the changes in diagnostic and follow-up standards in esophageal cancer, and how these have impacted upon and guide the various therapeutic options.

Melanoma
Joseph et al. emphasize that despite the recent approvals of new agents for metastatic melanoma, there remains a critical need for more effective agents. They review the current clinical data on sequencing and combination therapies and discuss future therapeutic strategies.

Hematologic Malignancies
Belli et al. review the myelodysplastic syndromes (MdS) with a focus on the different cytogenetic risk stratifications and the molecular backgrounds of the most relevant chromosomal findings.

Gynecological Oncology
Stringer and Fleming hypothesize that the combination of mToR inhibitors and hormonal therapies may be a useful therapeutic approach for endometrial carcinoma and discuss the growing interest to study this approach in clinical trials.

Supportive Oncology
hui and Bruera highlight the importance of supportive and palliative care in oncology and the need for oncologists to have a good working knowledge of major palliative care principles in order to maximize the quality of life for cancer patients.

Patient Care
Pipas et al. consider the promises and the future of individualized therapy (e.g. personalized medicine) given the rapid advances in cancer genetics and the novel targeted agents that are emerging in the clinical setting. Oncology & Hematology Review is grateful to all of the authors for sharing their expertise in order to provide an outstanding and thought-provoking issue reviewing the latest developments and future directions in these fast-moving fields. We trust that you will enjoy reading this issue!

Article Information:

Further Resources

Share this Article
Related Content In Breast Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72